# Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

> **NCT06493370** · PHASE2 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 48 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Intravenous ascorbic acid/vitamin C

## Key facts

- **NCT ID:** NCT06493370
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06493370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06493370, "Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06493370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*